Based on meta-analyses, degludec mediates equivalent reductions in HbA1c with a lower risk of hypoglycaemia compared with glargine U100 at a significantly lower total daily insulin dose in T1DM and T2DM with basal-only insulin [27, 28]. Here, INS is linked to type 2 diabetes mellitus.